See the DrugPatentWatch profile for Belatacept
When does belatacept’s patent expire?
Public patent-expiration timing depends on the specific patent family (drug substance vs. formulation vs. method-of-use), the country/jurisdiction, and any added exclusivity. The provided information does not include any belatacept patent numbers, filings, or jurisdictions, so an exact expiration date can’t be determined from here.
How can you find the exact expiration date for belatacept in your country?
To get the correct date, you need to match the marketed product to the relevant patent family and jurisdiction:
- Identify the exact marketed belatacept brand/product and strength used where you are (patent status can differ by country).
- Look up the company/patent assignee and the belatacept patent family in that jurisdiction (e.g., US vs. EP vs. UK vs. CA).
- Check each listed patent’s expiration plus any statutory adjustments or pediatric/other extensions, since “last relevant right” is what blocks generic/biosimilar entry.
- If the goal is biosimilar-style market entry analysis (belatacept is a biologic), also check for regulatory exclusivities (not just patents), because exclusivity can extend market protection even after a patent date.
Is belatacept protected only by patents, or also by regulatory exclusivity?
Market protection for biologics can involve both patents and additional regulatory exclusivity periods, so patent-expiration alone may not reflect when competitors can launch. The exact interaction depends on jurisdiction and the regulatory pathway used for follow-on products, but the underlying details are not provided here.
What happens when a key patent expires?
Once the last blocking patent/exclusivity ends (again, jurisdiction-specific), follow-on competitors can generally pursue approval and potentially launch, subject to:
- Whether other patents in the same family still cover the product or specific claims.
- Whether any later-expiring patents (new claims, additional indications, formulations) remain in force.
- Any litigation or settlement that can delay launch.
Why different sources show different “expiration” dates
Search results sometimes quote different dates because they may refer to:
- Different patents within the same family (drug substance vs. methods vs. formulation).
- Different geographies (each country has its own grant and expiration).
- Different definitions of “expiration” (granted term vs. earliest possible expiry vs. “last patent that blocks launch”).
To resolve this, you need the specific patent numbers and the jurisdiction.
If you share a jurisdiction, I can narrow it down
Tell me:
1) which country (or countries) you care about (e.g., US, EU/EP, UK, Canada), and
2) whether you mean “first patent expiry” or “last patent preventing launch,”
and I can help you identify what to check (and which patents typically control the effective market exclusivity).
Sources
No sources were provided in the prompt, so none are cited.